Matthew Lustig - Ventas Independent Director
| VTR Stock | USD 66.85 0.86 1.27% |
Director
Mr. Matthew J. Lustig is Independent Director of Ventas, Inc. Mr. Lustig is Managing Partner of North America Investment Banking and Head of Real Estate, Gaming and Lodging at Lazard Freres Co. LLC. He also heads the real estate private equity successor entities of Lazard as a Managing Director of LA1 Partners LLC . From May 2011 to December 2012, Mr. Lustig served as Chairman of the Board of Atria Senior Living, Inc. In addition, Mr. Lustig is or was a board member of several public and private portfolio investments of funds managed by LA1 or its affiliates. Prior to joining Lazard Freres Co. in 1989, Mr. Lustig was a First Vice President at Drexel Burnham Lambert and was previously a lending officer with Chase Manhattan Bank, specializing in credit, construction, and real estate finance since 2011.
| Age | 59 |
| Tenure | 14 years |
| Address | 353 North Clark Street, Chicago, IL, United States, 60654-4708 |
| Phone | 877 483 6827 |
| Web | https://www.ventasreit.com |
Matthew Lustig Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Lustig against Ventas stock is an integral part of due diligence when investing in Ventas. Matthew Lustig insider activity provides valuable insight into whether Ventas is net buyers or sellers over its current business cycle. Note, Ventas insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ventas'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Lustig over two months ago Acquisition by Matthew Lustig of 560 shares of Ventas at 57.96 subject to Rule 16b-3 | ||
Matthew Lustig over three months ago Acquisition by Matthew Lustig of 372 shares of Boston Properties subject to Rule 16b-3 | ||
Matthew Lustig over three months ago Acquisition by Matthew Lustig of 508 shares of Ventas at 63.89 subject to Rule 16b-3 | ||
Matthew Lustig over six months ago Acquisition by Matthew Lustig of 459 shares of Boston Properties subject to Rule 16b-3 |
Ventas Management Efficiency
The company has Return on Asset of 0.018 % which means that on every $100 spent on assets, it made $0.018 of profit. This is way below average. Ventas' management efficiency ratios could be used to measure how well Ventas manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to 0. In addition to that, Return On Capital Employed is likely to drop to 0.03. At this time, Ventas' Asset Turnover is relatively stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christann Vasquez | Healthcare Realty Trust | 60 | |
| John Abbott | Healthcare Realty Trust | 66 | |
| Roscoe Moore | Global Medical REIT | 76 | |
| Burke Whitman | Omega Healthcare Investors | 64 | |
| Robert Adams | National Health Investors | 74 | |
| Nancy Agee | Healthcare Realty Trust | 68 | |
| Ronald Marston | Global Medical REIT | 78 | |
| Charlotte Swafford | National Health Investors | 73 | |
| Huiqi Zhang | Global Medical REIT | 31 | |
| Kimberly Ouimet | National Health Investors | N/A | |
| Edward Lowenthal | Omega Healthcare Investors | 75 | |
| Robert McCabe | National Health Investors | 70 | |
| James Morey | Universal Health Realty | 52 | |
| Edward Braman | Healthcare Realty Trust | 64 | |
| Barbara Hill | Omega Healthcare Investors | 67 | |
| Paula Crowley | Global Medical REIT | 66 | |
| Colleen Schaller | National Health Investors | N/A | |
| Kapila Anand | Omega Healthcare Investors | 67 | |
| Stephen Plavin | Omega Healthcare Investors | 60 | |
| Matthew Cypher | Global Medical REIT | 44 | |
| Kevin Jacobs | Omega Healthcare Investors | 47 | |
Management Performance
| Return On Equity | 0.0084 | ||||
| Return On Asset | 0.018 |
Ventas Inc Leadership Team
Elected by the shareholders, the Ventas' board of directors comprises two types of representatives: Ventas inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ventas. The board's role is to monitor Ventas' management team and ensure that shareholders' interests are well served. Ventas' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ventas' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edmund III, Chief VP | ||
| Carey JD, General VP | ||
| Jay Gellert, Independent Director | ||
| Richard JD, Senior Advisor | ||
| Maurice Smith, Independent Director | ||
| Richard Gilchrist, Independent Director | ||
| Louise Adhikari, VP Communications | ||
| Robert Probst, Chief Financial Officer, Executive Vice President | ||
| J Hutchens, Executive Vice President - Senior Housing | ||
| Roxanne Martino, Independent Director | ||
| Justin Hutchens, Executive Officer | ||
| Randy Sohanaki, Vice President - IT Applications | ||
| Julie Robinson, Senior Investments | ||
| Brian Wood, Chief VP | ||
| John Cobb, Executive Vice President, Chief Investment Officer | ||
| Peter Bulgarelli, Executive Vice President and President and Chief Executive Officer, Lillibridge Healthcare Services, Inc. | ||
| Bhavana Devulapally, Senior Vice President, Chief Information Officer | ||
| Michael Embler, Independent Director | ||
| Walter Rakowich, Independent Director | ||
| Debra Cafaro, Chairman of the Board, Chief Executive Officer | ||
| Gregory Liebbe, Senior Vice President Chief Accounting Officer, Controller | ||
| Robert Reed, Independent Director | ||
| Timothy Sanders, Senior Investment Officer | ||
| Christian Cummings, Senior Housing | ||
| Melody Barnes, Independent Director | ||
| James Shelton, Presiding Independent Director | ||
| Matthew Lustig, Independent Director | ||
| Sean Nolan, Independent Director | ||
| Carey Roberts, Executive Vice President General Counsel and Ethics & Compliance Officer | ||
| Marguerite Nader, Independent Director |
Ventas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ventas a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0084 | ||||
| Return On Asset | 0.018 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 42.44 B | ||||
| Shares Outstanding | 437.14 M | ||||
| Shares Owned By Insiders | 0.56 % | ||||
| Shares Owned By Institutions | 99.90 % | ||||
| Number Of Shares Shorted | 12.45 M | ||||
| Price To Earning | 909.80 X |
Additional Tools for Ventas Stock Analysis
When running Ventas' price analysis, check to measure Ventas' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventas is operating at the current time. Most of Ventas' value examination focuses on studying past and present price action to predict the probability of Ventas' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventas' price. Additionally, you may evaluate how the addition of Ventas to your portfolios can decrease your overall portfolio volatility.